Trametinib and Fimepinostat May Be More Potent Than Approved Agents for MPNSTs in NF1 In preclinical studies, trametinib and fimepinostat outperformed selumetinib and mirdametinib in inhibiting NF1-related MPNST growth.

#Trametinib and #Fimepinostat demonstrated potent antitumor activity in malignant peripheral nerve sheath tumor (#MPNST) cell lines derived from patients with neurofibromatosis type 1 (#NF1). Study in Cancers.

Learn more: https://bit.ly/3Ntn2kL

#RareDisease #MedSky #NeurofibromatosisType1